Heron Therapeutics Inc. (HRTX) Given a $34.00 Price Target at Leerink Swann
Heron Therapeutics Inc. (NASDAQ:HRTX) received a $34.00 target price from investment analysts at Leerink Swann in a research note issued to investors on Saturday. The firm presently has a a “buy” rating on the biotechnology company’s stock. Leerink Swann’s price target points to a potential upside of 102.02% from the stock’s previous close.
A number of other equities research analysts have also recently weighed in on HRTX. Cowen and Company restated a “buy” rating on shares of Heron Therapeutics in a report on Saturday, July 9th. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. JMP Securities restated a “buy” rating on shares of Heron Therapeutics in a report on Friday, September 9th. Brean Capital assumed coverage on shares of Heron Therapeutics in a report on Tuesday, October 4th. They issued a “buy” rating and a $41.00 price objective on the stock. Finally, Jefferies Group cut their price objective on shares of Heron Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, October 3rd. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $42.29.
Shares of Heron Therapeutics (NASDAQ:HRTX) traded down 1.17% during midday trading on Friday, hitting $16.83. 638,526 shares of the stock traded hands. The company’s 50-day moving average is $18.62 and its 200 day moving average is $18.90. Heron Therapeutics has a 52 week low of $15.13 and a 52 week high of $31.32.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/09/heron-therapeutics-inc-hrtx-given-a-34-00-price-target-at-leerink-swann.html
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. On average, equities research analysts expect that Heron Therapeutics will post ($4.39) EPS for the current year.
In related news, insider Robert Rosen sold 100,000 shares of the stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the transaction, the insider now owns 102,640 shares in the company, valued at $2,391,512. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 20.31% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of HRTX. Schwab Charles Investment Management Inc. increased its position in shares of Heron Therapeutics by 8.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 111,768 shares of the biotechnology company’s stock worth $2,018,000 after buying an additional 8,772 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of Heron Therapeutics by 25.4% in the second quarter. Metropolitan Life Insurance Co. NY now owns 26,014 shares of the biotechnology company’s stock worth $470,000 after buying an additional 5,268 shares during the period. Panagora Asset Management Inc. increased its position in shares of Heron Therapeutics by 6.5% in the second quarter. Panagora Asset Management Inc. now owns 261,298 shares of the biotechnology company’s stock worth $4,716,000 after buying an additional 15,906 shares during the period. Barclays PLC increased its position in shares of Heron Therapeutics by 255.0% in the second quarter. Barclays PLC now owns 30,905 shares of the biotechnology company’s stock worth $558,000 after buying an additional 22,199 shares during the period. Finally, Parametric Portfolio Associates LLC bought a new position in shares of Heron Therapeutics during the second quarter worth $213,000.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.